Placental Growth Factor Human ELISA test

The main role of PlGF in tissues other than the placenta is angiogenesis in response to pathological ischemia or injury. In tumor cells, PlGF expression is part of the angiogenic switch that supports tumor vascularization. In most cancers such as renal cell carcinoma, colorectal, lung, gastric, breast and hepatocellular cancers, a positive correlation between cancer severity and PlGF mRNA expression and protein blood levels were observed, with an inverse relationship between PlGF and survival.
Angiogenesis also plays a key role in atherogenesis and is intimately associated with inflammation and a variety of pro- and anti-angiogenic factors. PlGF was shown to be upregulated in early and advanced atherosclerotic lesions, and elevated circulating levels of PlGF were measured in patients with atherosclerotic or ischemic heart disease. In patients with acute coronary syndrome, high plasma PlGF level within 12 h of symptom onset was shown to predict a poor prognosis in short and long-term. Many studies indicate that PlGF might be a biomarker for atherosclerosis, particularly plaque instability, myocardial ischemia, and for prognosis of the patients with cardiovascular disease. Accelerated atherosclerosis is one of the consequential complications of chronic kidney disease and hemodialysis and PlGF levels in serum and urine have been described to be increased in these patients with decreased renal function.